Cardiology Case Analysis - Hemant Govind Khare, 65 Years/M

Extracted Data Summary from Reports

• Diastolic dysfunction present (grade not fully visible but "systolic dysfunction is stained")
• LV systolic dysfunction
• LV Ejection Fraction (EF): approximately 19-25% (severely reduced - the report mentions values in that range)
• The impression reads: "LV is dilated... systolic dysfunction is present... Diastolic dysfunction is present"
• This confirms Heart Failure with Reduced Ejection Fraction (HFrEF)

• HbA1c: 8.6% - poorly controlled Type 2 Diabetes Mellitus
• Estimated Average Glucose (eAG): 200.12 mg/dL
• Creatinine: 1.1 mg/dL - borderline (eGFR likely ~55-65 for age 65)
• Serum Sodium: 136 (low-normal)
• Urea: 54.14
• Uric Acid: 9.6 mg/dL - HIGH (hyperuricemia)

• LDL elevated (values suggest dyslipidemia)
• Total Cholesterol, Triglycerides - readings visible but partially obscured; pattern consistent with diabetic dyslipidemia

• Hemoglobin: ~11.8 g/dL - mild normocytic anemia
• TLC, platelets within range

Clinical Diagnosis

Heart Failure with Severely Reduced Ejection Fraction (HFrEF) in a 65-year-old male with Type 2 Diabetes Mellitus (poorly controlled), Hyperuricemia, Mild Anemia, and likely Diabetic Dyslipidemia

Line of Treatment - Guideline-Directed Medical Therapy (GDMT)

1. SGLT2 Inhibitor (Class I, Level A - MANDATORY in all HFrEF, with or without T2DM)

• Dapagliflozin 10 mg OD OR Empagliflozin 10 mg OD
• Dual benefit here: reduces HF hospitalizations AND cardiovascular mortality (DAPA-HF trial: 26% reduction in composite endpoint), AND improves glycemic control (addresses HbA1c 8.6%)
• Also nephroprotective - important given creatinine 1.1
• Caution: monitor for UTI, genital mycotic infections; avoid if eGFR < 20

2. ARNI - Sacubitril/Valsartan (Class I, Level B-R)

• Sacubitril/Valsartan (Entresto) 24/26 mg BD, titrate up to 97/103 mg BD over 2-4 weeks
• Preferred over plain ACE inhibitor or ARB - the PARADIGM-HF trial showed 20% further reduction in cardiovascular death compared to enalapril
• If ARNI is not immediately available or affordable: start with Ramipril 2.5-5 mg OD or Enalapril 2.5 mg BD, then switch to ARNI
• Caution: Do NOT combine ARNI with ACE inhibitor (36-hour washout required). Monitor BP and creatinine (already 1.1 - watch closely)

3. Evidence-Based Beta-Blocker (Class I, Level A)

• Carvedilol 3.125 mg BD - start low, titrate every 2 weeks to target 25 mg BD
• Alternatives: Bisoprolol 1.25 mg OD (titrate to 10 mg OD) or Metoprolol Succinate XL 12.5 mg OD (titrate to 200 mg OD)
• Only carvedilol, bisoprolol, and metoprolol succinate have proven mortality benefit in HFrEF
• Start only when patient is euvolemic/compensated - do NOT start in decompensated state

4. Mineralocorticoid Receptor Antagonist - MRA (Class I, Level A)

• Spironolactone 25 mg OD (or Eplerenone if gynecomastia occurs)
• Titrate to 50 mg OD if tolerated
• Caution: K+ monitoring essential - check renal function and potassium within 1 week of initiation. If K+ >5.0 mEq/L or creatinine rises significantly, hold or reduce dose

5. Diuretic for Congestion Relief (Class I)

• Furosemide 40 mg OD (adjust based on fluid status, weight monitoring)
• Target euvolemia - daily weight monitoring, restrict sodium (<2g/day) and fluids (<1.5L/day)
• Add metolazone 2.5 mg OD if diuretic resistance develops

Additional Management for Comorbidities

Diabetes (HbA1c 8.6%)

• SGLT2 inhibitor (already above) will help glycemic control
• Add Metformin 500 mg BD with meals if eGFR adequate (>45) - titrate cautiously
• Avoid sulfonylureas and thiazolidinediones (worsens HF)
• GLP-1 agonists (liraglutide/semaglutide) are not indicated for glycemic improvement in HFrEF per current evidence

Dyslipidemia (Diabetic pattern)

• High-intensity statin: Atorvastatin 40-80 mg at night
• Target LDL < 70 mg/dL (very high cardiovascular risk patient)
• If TG > 500: add Fenofibrate

Hyperuricemia (Uric Acid 9.6 mg/dL)

• Allopurinol 100 mg OD, titrate to 200-300 mg
• SGLT2 inhibitor will also lower uric acid (bonus benefit)
• Avoid NSAIDs (worsen HF and renal function)

Anemia (Hb 11.8)

• Evaluate iron stores: send serum ferritin, TSAT (iron deficiency anemia is common in HFrEF and independently worsens outcomes)
• If iron deficient (ferritin <100 or TSAT <20%): IV iron (Ferric Carboxymaltose) - shown to improve symptoms and quality of life in HFrEF (AFFIRM-AHF trial)
• Check B12/folate levels (B12 appears high here, so megaloblastic anemia unlikely)

Vitamin D (87.6 ng/mL)

• Currently sufficient - no supplementation needed. In fact, at levels >100, monitor for toxicity (hypercalcemia). If patient is on Vitamin D supplements, consider reducing dose.

Device Therapy Considerations

• Reassess LVEF after 3-6 months of optimized GDMT - EF may improve
• If LVEF remains ≤35% despite 3 months of GDMT + LBBB morphology on ECG with QRS ≥150 ms: consider CRT (Cardiac Resynchronization Therapy) referral
• If LVEF remains ≤35% despite GDMT: ICD implantation discussion (primary prevention of sudden cardiac death) - Class I indication in ischemic or non-ischemic CM

Investigations to Order Now

1. ECG - assess QRS morphology (LBBB?), rate, rhythm
2. NT-proBNP or BNP - baseline severity marker
3. Serum electrolytes (Na, K) - before starting MRA and ARNI
4. eGFR calculation - full CKD-EPI using age, creatinine
5. Serum Ferritin + TSAT - work up anemia
6. 2D Echo with EF confirmation - if EF reading unclear
7. Thyroid function (TSH) - hypothyroidism can cause dilated cardiomyopathy
8. Coronary angiography - if ischemic etiology of cardiomyopathy is suspected (common cause of reduced EF in a diabetic male)
9. 24-hour Holter - if arrhythmia suspected

Key Monitoring Parameters

Summary Algorithm

HFrEF (EF ~20-25%) + T2DM + Hyperuricemia + Mild Anemia

Step 1 (Start Together):
→ SGLT2i (Dapagliflozin 10mg) [HF + glycemic + renal protection]
→ ARNI (Sacubitril/Valsartan) [RAAS blockade]
→ Beta-blocker (Carvedilol 3.125mg BD) [once compensated]
→ MRA (Spironolactone 25mg) [aldosterone blockade]
→ Furosemide [symptom relief]

Step 2 (Comorbidities):
→ Atorvastatin 40-80mg [LDL target <70]
→ Allopurinol 100mg [uric acid 9.6]
→ IV iron [if Fe-deficient anemia confirmed]

Step 3 (3-6 months):
→ Reassess EF → ICD/CRT if EF remains ≤35%
→ Coronary angiography if ischemic etiology unclear

Important Disclaimer: This analysis is based on the visible lab/echo data and current evidence-based cardiology guidelines (2022 AHA/ACC/HFSA, 2024 ACC Expert Consensus). Final treatment decisions must be made by the treating cardiologist after full clinical examination, complete symptom assessment, medication allergy history, and review of all investigations. Drug doses must be individualized based on BP, renal function, and tolerance.

• 2024 ACC Expert Consensus for HFrEF
• DAPA-HF trial (Dapagliflozin in HFrEF - PMID 40352167 systematic review)
• EMPEROR-Reduced (Empagliflozin in HFrEF)
• Fuster and Hurst's The Heart, 15th Edition, SGLT2 Inhibitors section

ICD & CRT Guidelines for This Patient (LVEF ~20-25%)

Patient Profile Recap

• 65-year-old male, HFrEF with severely reduced LVEF (~20-25%)
• Type 2 DM (HbA1c 8.6%), Creatinine 1.1 mg/dL
• Currently NOT on GDMT (just diagnosed / initiating treatment)

STEP 1: DO NOT IMPLANT A DEVICE YET

Data from the PROVE-HF study showed that 32% of HFrEF patients improved LVEF above 35% at 6 months and 62% at 12 months after starting ARNI therapy - meaning they no longer met ICD criteria at that point. Starting triple/quadruple GDMT in newly diagnosed HFrEF reduced the proportion requiring ICD by twofold at 3 months and threefold at 6 months.

ICD: Primary Prevention Guidelines

Class I Indication (Strongest - "Is Recommended") | AHA/ACC/HFSA 2022

Special Consideration: Ischemic vs. Non-Ischemic Etiology

• Ischemic cardiomyopathy (post-MI): ICD after ≥40 days post-MI, LVEF ≤35%, NYHA II-III - Class I, Level A
• Non-ischemic DCM: ICD benefit confirmed - Class I, Level A in ACC/AHA; ESC has slightly downgraded to Class IIa (based on DANISH trial controversy)
• This patient needs coronary angiography to determine etiology - this directly impacts the strength of ICD recommendation

Special Note: NYHA Class IV

• If NYHA Class IV and candidate for advanced HF therapy (transplant/LVAD bridge): ICD is Class IIa
• If NYHA Class IV and NOT a candidate for advanced HF therapy: ICD should NOT be implanted (Class III: No Benefit)

CRT: Cardiac Resynchronization Therapy Guidelines

Decision Matrix (2022 AHA/ACC/HFSA + Braunwald's Heart Disease)

CRT Device Choice: CRT-P vs. CRT-D

New Evidence (2024-2025): GDMT Reduces SCD Risk Before Device

Dapagliflozin reduced the composite of serious ventricular arrhythmia, resuscitated cardiac arrest, or SCD by 21% (HR 0.79, p=0.03) - independent of ICD.

Emerging Technology: Wearable Cardioverter-Defibrillator (WCD)

• LifeVest (WCD) - worn externally, detects and shocks VF automatically
• Class IIb recommendation as a bridge to ICD reassessment
• Limitation: compliance issues (skin irritation, alarms), less effective when not worn

Cardiac Contractility Modulation (CCM) - Newer Option

• NYHA II-III symptoms despite GDMT
• LVEF 25-45%
• QRS < 130 ms (i.e., NOT suitable for CRT)
• Approved by FDA (OPTIMIZER Smart System)
• Improves symptoms and exercise capacity but NOT proven to reduce mortality

Practical Decision Algorithm for THIS Patient

NOW (Immediately):
├── Start GDMT (SGLT2i + ARNI + BB + MRA + Furosemide)
├── Obtain 12-lead ECG → Check QRS duration + morphology (LBBB?)
├── Obtain 24-hour Holter → Look for NSVT, AF
└── Coronary angiography → Ischemic vs. non-ischemic etiology?

AT 3 MONTHS (Reassess LVEF):
├── LVEF improved to >35%?
│   ├── YES → Continue GDMT, no device needed yet
│   │          Reassess at 6-12 months
│   └── NO (LVEF still ≤35%) → PROCEED TO DEVICE
│       ├── ECG: LBBB + QRS ≥150 ms?
│       │   ├── YES + NYHA II-III → CRT-D (Class I)
│       │   └── NO (QRS <120ms) → ICD alone (Class I)
│       └── NYHA class?
│           ├── II or III → ICD (Class I, Level A) ✓
│           └── IV (no advanced HF candidacy) → No ICD (Class III)

IF NEAR-TERM SCD RISK CONCERN DURING WAIT:
└── Consider WCD (wearable defibrillator) as bridge

Key Numbers for This Patient

• 2022 AHA/ACC/HFSA Heart Failure Guidelines (full text)
• 2024 ACC Expert Consensus for HFrEF Treatment
• Braunwald's Heart Disease, Guidelines for CRT/ICD in HFrEF, p. 321
• Fuster and Hurst's The Heart, 15th ed., CRT section, p. 1549
• Harrison's Principles of Internal Medicine 22e (2025), Fig. 286-6
• PROVE-HF, DAPA-HF post-hoc analysis, MADIT-CRT, RAFT, SCD-HeFT landmark trials